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ABSTRACT  
Information Technologies can provide the basis for new directions in cancer 
research, supplying tools that identify subtle but important signs from the 
analysis of clinical, behavioral, environmental and genetic data. The purpose 
of this paper is to describe and analyze the system developed for managing 
Banco Nacional de Tumores (SISBNT) – National Tumor Bank System - 
highlighting its role in the technological innovation of Instituto Nacional do 
Câncer (INCA) – Brazilian National Cancer Institute. It is a qualitative 
empirical theoretical paper, descriptive and exploratory in nature, based on 
the single case study method and on participant observation. The results show 
the importance of good practices in information management for the full 
operation of a biobank in a research-oriented pharmaceutical company. There 
is also evidence that the implementation of SISBNT has contributed to the 
improvement of cancer treatment quality and to the support of efforts towards 
the organization of the integration of clinical, translational and basic research. 
The non-use of data mining techniques for the identification of molecular 
patterns and structures associated with the different types of cancer 
undergoing study at INCA seems to occur due to the early stage of 
Bioinformatics and translational research, as well as the National Tumor 
Bank, in the institution. 
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1. INTRODUCTION 
 
According to the World Health Organization, 2014, one out of eight deaths in 
the world is caused by cancer. In Brazil, there is a complex scenario in cancer 
treatment. The occurrences and rates of death have been growing, around 576,000 
cases every year: they are particularly high when it comes to prostate cancer in men 
and breast cancer in women. Research has found that waiting lines for treatment and 
diagnosis have become commonplace in many regions of the country, resulting in 
patients being diagnosed at advanced stages of the disease.  
According to the Rede Brasileira de Pesquisas sobre o Câncer – Brazilian 
Cancer Research Network – cancer is a disease caused by the buildup of genetic and 
epigenetic modifications in the genome of a normal cell. Such modifications result 
from errors that occur during DNA replication and exposure to mutagenic agents and 
agents in the cell metabolism. In addition, according to the Brazilian Cancer Research 
Network, “the identification of the modified genes in tumor cells which are directly 
related to tumorigenesis has been the main focus of cancer genetics research over the 
last 30 years.”  
Promptness in referring patients to proper therapeutic procedures, with a short 
waiting time, is essential to increase survival rates, improve quality of life and the 
chance of being cured.  Being diagnosed early is one of the most critical success 
factors: it is, therefore, essential to create organizational mechanisms that simplify the 
access to pertinent information and to health care services in order to reduce the 
fragmentation of the services and to speed up diagnosis time and beginning of cancer 
treatment. 
In the Brazilian context, Instituto Nacional do Câncer (INCA) – Brazilian 
National Cancer Institute – is the federal agency in charge of setting and implementing 
assistance, education and cancer prevention policies, with a specific coordination team 
based in the city of Rio de Janeiro. Ever since 1997, INCA has made huge changes in 
its organization, with the aim of transforming its Research Center (RC) into a 
Technological Development Center (TDC) that is capable of leading Brazilian efforts 
towards the development of drugs in the oncology therapeutic class. From this 
background of change, Information and Communication Technologies (ICTs) have 
played a relevant role in supporting R&D activities. 
The Rede de Atenção Oncológica (RAO) - Oncologic Attention Network - is 
the main vehicle through which the Brazilian National Cancer Institute (INCA) bases 
its national integration plan on. Its purpose is to establish a partnership between 
organizations responsible for research and services in the cancer area.  This network 
translates into a cooperation environment with the aim of joining doctors, 
administrators and society segments that represent patients. Its goals are the following: 
i) to make the access to information and knowledge easy on all spheres – doctors, 
hospital administrators and patients; ii) to create a community for the practice of 
research and treatment; iii) to develop a friendly environment and easy access to 
relevant information to support clinical and administrative decision-making processes. 
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Cancer-related research is a long, complex and high-risk process and involves a 
myriad of organizations (Goldblatt & Lee, 2010).  Brazil still does not have a suitable 
public structure for the storage of tumor samples used in different cancer research 
lines. Hence, the creation of a biobank and of an IT architecture that provides easy 
information access is critical in order to speed up research projects and reduce the 
fragmentation of the databases used. According to the World Health Organization 
(2009), the biobank represents an organized collection of human biological material 
and associated information, collected prospectively and specifically stored for research 
purposes, in accordance with recommendations and technical, ethical and pre-defined 
operational standards. 
This reality highlighted the need to establish policies that aim to create a 
national bank of tumor samples (National Tumor Bank). The first step towards it was 
the investment in the development of technological infrastructure. One important 
decision was the implementation of a system that could support the network of 
organizations involved in the collection and processing of normal and tumor tissue 
samples, blood and clinical data of the most relevant tumors in Brazil, becoming a 
necessary tool for the advancement of research at INCA. 
Studies show that there is a big potential for theoretical and empirical research 
on the use of Information Science and IS Management to support cancer treatment and 
prevention (Clauser, Wagner, Aiello Bowles, Tuzzio, & Greene, 2011; Krysiak-Baltyn 
et al., 2014; O’Brien M., Kaluzny D., & Sheps G., 2014; Peterson, Bensadoun, Lalla, 
& McGuire, 2011; Pitassi, Gonçalves & Moreno, 2013). 
This study broadens scientific knowledge in these areas, in an attempt to 
answer the following research question: how can modern information and 
communication technologies contribute to the management of technological 
innovation in health care, in particular in a biopharmaceutical company, which 
operates in an oncology therapeutic class? In this sense, the specific purpose of this 
paper is to describe and analyze the system developed for the management of Banco 
Nacional de Tumores (SISBNT) – National Tumor Bank System - highlighting its role 
in basic, translational and clinical research at INCA (Brazilian National Cancer 
Institute) in Brazil. 
 
2. THEORETICAL FRAMEWORK 
 
As shown by Pronovost and Goeschel (2010), most countries have been facing 
serious problems in healthcare, arising from: i) the increase in the demand for 
healthcare due to the growth in the number of elderly citizens with chronic diseases;  
ii) higher demand for accessibility to extra hospital care which ensures efficiency, 
equality and individualization of healthcare; iii) limitation of financial resources; iv) 
difficulty recruiting and retaining personnel.  Medical resources, such as specialized 
personnel, hospital beds and state-of-the-art equipment, are usually costly, which 
results in a huge budgetary pressure.  These challenges help to transform highly 
complex services, such as cancer treatment, into high relevance areas for the 
organizations that operate therein (Goldblat & Lee, 2010).  
Healthcare organizations have generated massive amounts of data distributed 
on hospital information systems, patient electronic records, administrative systems, etc 
(Côrtes & Côrtes, 2011). However, most of this effort has proven unfruitful, as this 
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information is hardly ever effectively used in decision-making processes (Abidi, 
1999).  According to this reality, there is a need to create an environment in healthcare 
organizations that makes it easy to transform all this raw information into knowledge 
(Barbosa et al., 2009). Therefore, as determined by Wickramasinghe (2000), 
researchers, doctors, nurses and other professionals in healthcare can be referred to as 
sophisticated knowledge workers.  
They have the means of production, specialists´ skills and training obtained 
throughout the years of formal learning and education, using this experience in clinical 
decision-making processes and treatment of diseases.  Knowledge management in 
healthcare organizations can be defined as a combination of concepts and techniques 
to make it easy to create, indentify, acquire, develop, disseminate and use intellectual 
capital (O’Leary, 1998), whose creation and dissemination take place by means of 
multidisciplinary teams (Fried et al, 1998). 
It is important to highlight that cancer patient services are inherently 
multidisciplinary, involving the primary care doctor, the pathologist, the oncologist 
and the surgeon (O’Brien M. et al., 2014; Peterson et al., 2011). The quality of these 
services has been affected by the limited number of qualified oncology professionals 
and by the reduced number of research professional networks specialized in complex 
scientific disciplines that involve cancer treatment (Rastogi, Hildesheim & Sinha, 
2004; Lenoir, 1998). The use of information technology can contribute significantly to 
the improvement of healthcare (Abraham, Nishihara, & Akiyama, 2011; Bardhan & 
Thouin, 2013; Côrtes & Côrtes, 2011). For instance, Galligioni, Berloffa and Caffo 
(2009) describe their experiences in the development and use of electronic records of 
medical oncology patients to support research in this area. These records have been 
designed carefully in order to integrate the spectrum of cancer information and to 
allow it to be shared between researchers, stressing the importance of the use of 
Information and Communication Technologies (ICTs). 
Despite such reports as the one by Galligioni et al. (2009), the implementation 
of Information Systems (IS) has basically scratched the surface of possibilities and the 
potential of applying Information Science to healthcare (Wallace, 2007), especially in 
the context of developing countries (Turan & Palvia, 2014). Such authors as Catanho, 
Miranda and Degrave (2007) and Wallace (2007) suggest that basic research using 
information and communication technologies can provide resources for new directions 
in clinical sciences. In the context of cancer treatment, Bash et al. (2004) present three 
fundamental lines of work. The first line has its focus on state-of-the-art clinical 
medicine, which can include therapies based on evidence and sophisticated and 
personalized studies on the nature of the patients´ tumor and its biological 
characteristics. The second line regards the systemic approach of the patients´ care and 
needs (physical, psychosocial, functional and spiritual). The third line regards the use 
of Information and Communication Technologies that support clinical medicine geared 
towards patients and their care. 
As far as the first line is concerned, cell and molecular-related studies 
generated a large number of data related to genetic mapping and protein structures, 
turning Biology into a “mathematical” science and, increasingly, based on information 
(Lenoir, 1998). Researchers in Pharmacogenomics and Pharmacoepidemiology need 
this and other types of information in order to understand why patients respond 
differently to the treatment with certain drugs, both regarding adverse effects and 
efficiency in the treatment (Kim & Gilbertson, 2007). It is noticed, however, the 
importance of modern information technologies to provide the collection, management 
The case of Inca´s National Tumor Bank management system in Brazil                              553 
 
JISTEM, Brazil   Vol. 11, No. 3, Sept/Dec., 2014 pp. 549-568      www.jistem.fea.usp.br           
 
and processing of such data in an efficient and efficacious fashion. In general, their 
introduction in cancer research and treatment institutions means opportunities for the 
development and adoption of organizational innovations. 
According to the Oslo Manual - The Organization for Economic Co-operation 
and Development (1997), technological innovations comprehend the implementation 
of technologically new products and processes, and meaningful technological 
improvements in products and processes. At the organizational level, innovation “[...] 
implies combining different types and parts of knowledge and transforming them into 
useful products and services” (Figueiredo, 2009, p.31). In the biopharmaceutical 
industry, technological innovation, characterized by the systematic discovery of new 
drugs or of new uses for the drugs already on the market, depends on the mastering and 
integration of various scientific disciplines, such as Molecular Biology, Fine 
Chemicals, Computer Science, Information Science, Physics, Optics, and Mechanical 
Engineering, among others (Pitassi, Moreno & Gonçalves, 2014). Therefore, the 
discovery of new drugs depends on the technological capability built by the 
organization in a variety of areas (Moreira & Pitassi, 2013). Given these 
characteristics, the pharmaceutical industry was one of the trailblazers in adopting 
open innovation models (Hughes & Wareham, 2010). Traditional linear and vertical 
models of innovation, such as the Innovation Funnel (Cooper, 1993), reflect a concern 
on the part of the companies regarding the “false positive”, in view of the magnitude of 
the investments usually made in the development of new products (Chesbrough, 2006).  
In the current technical productive paradigm, due to the risks and costs involved, 
innovation is established as an interdepartmental and inter-organizational process (Bell 
& Figueiredo, 2012). Therefore, open innovation models are currently predominant in 
organizations, including Brazilian organizations, which seek to dynamize in-flows and 
outflows of knowledge and technology (Pitassi, 2014). 
Biopharmaceutical organizations, which focus their research on the oncology 
therapeutic class, have resorted to (with the purpose of creating more new drug 
production opportunities) translational research, which guides research from “the 
bench to the bedside”, as a mechanism to promote the integration between 
advancements resulting from basic research and clinical trials (Goldblat & Lee, 2010). 
According to Chiaroni, Chiesa and Frattini (2008), basic research in 
biopharmaceuticals is done at three essential stages: i) identification of the disease 
genetic base; ii) identification of the compound for the treatment of the disease; iii) 
pre-clinical tests. As for cancer, basic research is necessary for the advancement of 
knowledge on genetic mutation causes that lead to the different stages of the disease 
(Goldblat & Lee, 2010). 
Studies on the possible causes of the poor performance of the information sent 
out by DNA then gave rise to the research in: Genomics, which analyzes genetic 
sequencing, aiming to quantify the gene expression in cells; Proteomics, which carries 
out experiments to identify the structure of proteins and their functions in living 
organisms; molecular dynamics, which simulates the physical movement of atoms 
and molecules (Lenoir 1998). 
In general, a clinical trial or clinical study  is defined by Good Clinical Practice 
(GCP) as “any investigation in human subjects intended to discover or verify the 
clinical, pharmacological, and/or other pharmacodynamic effects of an investigational 
product(s), and/or to identify any adverse reactions to an investigational product(s), 
and/or to study absorption, distribution, metabolism, and excretion of an 
investigational product(s) with the object of ascertaining its safety and/or efficacy. In 
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the cancer studies, basic research in Molecular Biology is essential for the 
identification of new drugs and the a priori assessment of their positive and negative 
effects on the treatment of the disease. The development of this type of research is 
considerably driven forward by the availability of biological samples (Goebell & 
Morente, 2010). In this sense, biobanks have been developed in many countries with 
tumor samples (Specimen Central, 2014). 
According to the World Health Organization (2009), a biobank is an organized 
collection of human biological material and associated information, collected 
prospectively and stored for research-related purposes in accordance with 
recommendations or pre-defined operational, ethical and technical standards. The 
challenges to establish, develop and sustain biobanks with the required size and scope 
for clinical studies are highlighted in the literature (McQueen et al., 2014). 
The contribution of comprehensive and structured biobanks, as determined by 
good information management practices, is seen as a condition for the advancement of 
translational research on cancer, owing to the difficulty perceiving standards from the 
variety of causes and manifestations of the disease (Goebell & Morente, 2010). Thus, 
it is necessary to stress the importance of the standardization of processes for the 
integrity of the stored samples (Malm et al., 2013), as well as the potential for the use 
of data-mining techniques in translational research (Krysiak-Baltyn et al., 2014). 
 
3. METHODOLOGY  
 
The empirical theoretical study described in this paper is a field research, with a 
qualitative approach, descriptive and exploratory in nature (Vergara, 2005). It is 
descriptive as it shows the motivations for the implementation and main functionalities 
of Banco Nacional de Tumores (SISBNT) – National Tumor Bank System. It is 
exploratory as it seeks to analyze the contribution that SISBNT makes towards the 
integration between clinical, translational and basic research, a process that is still at an 
early stage in Brazilian pharmaceutical companies. 
The study adopts the single case study method (Yin, 1994), having semi-
structured interviews and participant observation as the main ways of data collection 
(Checkland, 1991). The case study, to the extent it takes dimensions of time and space 
into account (Yin, 1994), has proven to be a suitable methodological tool for the 
analysis of a phenomenon whose development occurred concomitantly to the huge 
structural changes that had taken place at INCA as of the second half of the 1990s. 
The choice of emblematic cases is a suitable scientific procedure due to the 
opportunity to understand specific dynamics; therefore, they can teach important 
lessons to organizations with the same mission statement or organizational objectives 
(Yin, 1994). Choosing INCA as a single case owes to the fact that the organization is 
the most qualified in Brazil to perform all the translational research stages in the 
oncology therapeutic class and to the efforts of incorporating ICTs made by the 
institute over the last years. 
The research analysis unit consisted of organizational units involved in the 
development and use of the National Tumor Bank (NTB), herein seen as components 
of a broad information system, supported by equipment and computer technologies. 
The focus of data collection and analysis was on the role of SISBNT in the 
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management of the information generated at the biobank and applied to basic, 
translational and clinical research activities. 
Field data collection took place by two different methods. One of the authors of 
this paper was a member of INCA´s Information Technology Division when this 
research was being done, working on the development and implementation of the 
organization’s IT strategy.  As such, he could closely monitor the development and 
implementation of SISBNT, interacting with the various actors and technological 
artifacts involved. In addition to the data obtained from the documents related to this 
process, the researcher´s own perceptions were used as an input for the analysis of the  
investigated phenomena herein. 
Consequently, the first method of data collection - participant observation, -
performed by him was selected (Argyris, Putnam & Smith, 1985): this method is 
justified because it was intrinsically associated to the implementation of the Banco 
Nacional de Tumores (SISBNT) – National Tumor Bank System. 
In the second data collection method, the researchers conducted five semi-
structured interviews with the persons in charge of the implementation of SISBNT in 
the area of Information and Communication Technologies and with five 
representatives of the areas of the Research Center  (users of the system) including the 
manager of the SISBNT.  The interviews had been conducted over the first six months 
of 2011, based on a script with open questions, and structured from the literature 
review used in the research.  Its main purpose was the collection of evidence regarding 
the role that SISBNT had been developing in basic, translational and clinical research 
in oncology. 
The choice of the interviewed subjects was intentional, made from the 
identification of the key actors in the process of the implementation of the National 
Tumor Bank. The fact that one of the researchers was in charge of INCA´s ICT 
contributed not only to the identification of these subjects, but also to the scheduling 
and quality of the interviews. All the interviews were conducted on the premises of 
INCA and recorded with the consent of the interviewees. All the answers were 
transcribed for later analysis. 
The data collected was treated by the thematic or categorical content analysis 
method, triangulating the frequency in which terms and ideas present in the recorded 
answers occurred, with the observations and data obtained by the aforementioned 
researcher, in light of the concepts and constructs selected in the literature (Bardin, 
1998).  This researcher´s experience in the implementation of SISBNT was also 
important to the interpretation of the interviewees´ cognitive activity. 
It is important to highlight the limitations of this method, given the subjectivity 
inherent to the interpretation of the researchers´ accounts during data analysis. In order 
to reduce this problem, the researchers´ interpretations, emerging at the data analysis 
stage, were sent to the interviewees for later corrections. However, no correction 
requests were received by the team.  
 
4. THE CASE OF INCA´S NATIONAL TUMOR BANK 
 
INCA is an organization from the Health Ministry, responsible for the 
development of activities and their coordination for the prevention and control of 
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cancer in Brazil. INCA´s hospital units are located in the City of Rio de Janeiro, 
integrating the Sistema Único de Saúde (SUS) – Unified Health System – and offer a 
full treatment to people with cancer. Patients with mobility issues, or without clinical 
conditions to attend outpatient appointments, are visited regularly at their homes by 
interdisciplinary teams.   Today, INCA is a landmark institution in Latin America 
when it comes to clinical trials for oncology therapeutic class. INCA is an  active 
member of the Rede Brasileira de Pesquisas sobre o Câncer  – Brazilian Cancer 
Research Network – whose strategy is the unification of basic, translational and 
clinical research on the disease. INCA is also a member of the Rede Nacional de 
Pesquisa Clínica em Hospitais de Ensino - National Clinical Research Network in 
School Hospitals – whose purpose is to be an institutional model in clinical studies, 
based on the best research practices, aimed at the Sistema Único de Saúde (SUS) – 
Unified Health System. Currently, the network is composed of 20 units associated with 
university institutions, serving all Brazilian regions, with the purpose of incorporating 
regional research vocations into development practices, in a decentralized management 
perspective. 
 
4.1 The Banco Nacional de Tumores (SISBNT) – National Tumor Bank 
System 
Over the last few years, INCA has been investing significantly in the 
implementation of an IT architecture that integrates the organization´s main processes 
and departments and that provides the exchange of information and cooperation 
between the institute, clinics and laboratories, distributed in its hospital units. 
Over the last ten years, the focus of the IT corporate unit has been on the 
management systems and medical assistance systems, seeking to standardize 
equipment and software and to unify access codes (single registration). In 2005, INCA 
developed a project with the purpose of establishing a network for collection and 
processing of normal and tumor tissue samples, blood and clinical data of the most 
relevant tumors in Brazil (in relation to their frequency and morbidity). This network is 
composed of cancer university medical centers and hospitals, including INCA´s 
hospitals, totaling 20 centers in the five geographic regions of the country. 
The centers were chosen based on their potential to recruit patients and on the 
availability of trained personnel for diagnosis, sample collection and data processing. It 
is important to highlight the fact that such activities are performed in accordance with 
protocols defined by INCA for collection, identification, storage and transference of 
samples obtained by the members of the network to the institute’s Research Center. 
The National Tumor and DNA Bank lies central in the aforementioned project, 
created with the purpose of supporting studies in the area of markers in diagnosis and 
therapy, in significant samples of the Brazilian population. INCA´s National Tumor 
Bank consists of a biobank, with the clinical history data of patients who donated their 
samples to the institute, and of a physical repository for the cells obtained from such 
samples, in order to carry out clinical trials, and for use in basic research projects. Its 
development allows the standardization and computerization of the sample collection 
procedures, clinical data records and monitoring of patients for prospective studies, 
which may be used as a model for routine hospital conduct. 
The Banco Nacional de Tumores (SISBNT) – National Tumor Bank System – 
is an information system developed by INCA´s corporate IT department, in order to 
support the National Tumor Bank, depending on the demand of the institution´s 
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Research Centre. As it can be seen in Figure 1, the process that SISBNT supports 
consists of six stages and involves professionals from such areas as Pathology, Surgery 
and Laboratory. 
 
 
Figure 1 – National Tumor Bank´s Workflow Process 
Source: by the authors 
The National Tumor Bank team’s internal workflow process is initiated with 
the signature of the informed consent document, in which the patient authorizes the 
collection of their tissue and blood samples during the surgical procedure they are 
undergoing. Collection procedure is performed directly in the operating theater of the 
National Tumor Bank´s associated hospitals. In the hospitals, there is a computer 
where the technician in charge of registering samples can perform a patient search by 
means of three different options: patients´ registration, number of the informed consent 
document, or number of the examination done on the pathological anatomy system, 
which is integrated to the Banco Nacional de Tumores (SISBNT) – National Tumor 
Bank System. 
The technician in charge inputs the date and time of the collection 
(automatically entered with current date and time, but with the possibility of changing 
them in cases of previous date and time entry on the system). The system enables the 
sample-adding function where the user can add tissue samples and/or fluids to the 
same collection. For every new sample, the technician in charge inputs the class type 
(tissue or fluid) and fills out the fields with the characteristics of the sample, listed in 
Chart 1. Figure 2 shows the screen of the Banco Nacional de Tumores (SISBNT) – 
National Tumor Bank System - with which the technician interacts at this stage of the 
process. 
 
Tissue Class Type Characteristic Fluid Class Type Characteristics  
Type of receiver (tube or microscope 
slide)  
Type of receiver (tube or microscope 
slide) 
Part region (A, B, C...) Subclass 
Subclass Topography 
Pathological state Type of procedure 
Type of procedure Information on blood transfusion 
      
1 2 3 4 5 6 
Sample 
Collection  
Sample 
Shipping 
Sample 
Receipt 
 
Sample 
Removal    
Sample 
Processing  
Sample  
Storage   
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Tissue Class Type Characteristic Fluid Class Type Characteristics  
Topography Information on chemotherapy 
Side Information on anticoagulant 
Type of preservation Time of the collection 
Observation Type of preservation 
 Volume 
Chart 1: Characteristics of the Sample Type per Class 
Source: by the authors 
 
Figure 2 – Sample Collection 
At the end of the sample collection, the technician generates a report containing 
information on the samples they entered on the system. This report is sent to the 
National Tumor Bank, together with the receiver of the collected samples. After 
receipt, the condition of the sample is defined; it can be removed (the sample is 
removed from the bank due to quality issues) or processed, which develops one of the 
following conditions: restrict use (sample restricted for the National Tumor Bank´s use 
only), available (sample available for research), unavailable (sample unavailable for 
research), depleted (sample that originated secondary components), and reserved 
(reserved for some research). 
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The National Tumor Bank´s storage process is initiated by the barcode reading 
of the primary sample, from which their secondary components are extracted. 
According to the class and type of preservation of the primary sample, other types of 
secondary components are obtained, such as: serum, DNA, RNA, proteins, plasma, 
total leukocytes, mononuclear cells, layers, manipulated tissue and supernatant fluids. 
In order to store a sample, the system needs to provide a map with the available 
positions in the National Tumor Bank´s physical storage where they can be stored 
(Figure 3). The technician in charge informs which batch (it is possible to choose one 
among all the batches received and not stored, according to the Banco Nacional de 
Tumores (SISBNT) – National Tumor Bank System), chooses the samples to be 
positioned and performs their allocation on the system. 
The samples are allocated the first free positions in a receiver, complying with 
the criterion established for the storage conditions (for instance, blood can only be 
stored in the –80º freezer and marrow bone, in the –40º one). After the end of the 
allocation entered on SISBNT, a report is automatically generated, informing the 
technician in charge where each sample is going to be stored physically. 
The Banco Nacional de Tumores (SISBNT) – National Tumor Bank System – 
also has a search tool that finds the receivers on the system, as well as their storage 
tree, as seen in Figure 3.  It is possible to navigate through its boxes and positions and 
select one of them in order to obtain a summary of the information on the sample 
therein stored. 
 
 
Figure 3 – Storage Map 
560    Gonçalves, A. A., Pitassi, C., Assis Jr. V., M., de 
 
JISTEM, Brazil   Vol. 11, No. 3, Sept/Dec., 2014 pp. 549-568      www.jistem.fea.usp.br           
 
In addition to the information on the samples, made available by the search in 
the freezer, the system also provides a sample search by code or donor.  By using the 
sample code or donor´s registration, the technician in charge is able to obtain all the 
information on the sample, as well as the characteristics of their collection, 
pathological anatomy, clinical laboratory and storage. Figure 4 shows the screen 
related to this type of search. 
 
 
Figure 4 – Sample search by code or donor 
  
The Banco Nacional de Tumores (SISBNT) – National Tumor Bank System – 
has been implemented successfully in four different hospitals in Rio de Janeiro. The 
system shows an average of 500 searches, made by 237 registered users with 
management, operational and search profiles. Up until the date of this research, 26.363 
samples had been collected and stored at the National Tumor Bank. In addition, 19.721 
informed consent documents had been signed and 19.401 clinical questionnaires had 
been answered. 
Due to the nature of storing data and the need to protect the privacy of the 
patients, the Banco Nacional de Tumores (SISBNT) – National Tumor Bank System 
cannot be accessed directly by INCA´s researchers. It has its own team for the 
management of the system, which is also responsible for providing the information 
requested in the experiments. In fact, in order for the researchers to have data available 
to their project, they first need to sign the terms and conditions at INCA´s ethics 
committee. Therefore, the National Tumor Bank can be regarded as the facility for the 
institute´s basic, translational and clinical research. 
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4.2 The Banco Nacional de Tumores (SISBNT) – National Tumor Bank 
System – and INCA´s Innovation Management  
There was a consensus on INCA´s executive board of directors towards the fact 
that the institute needed to focus its strategic actions on the advancement of cancer 
knowledge in Brazil. Aligned with this consensus, the role of R&D has taken shape 
since the middle of the last decade, seeking to transform INCA´s Research Center into 
a Technological Development Center. Among all the initiatives regarded as critical for 
research to move on to the next level, the National Tumor Bank stands out in the eyes 
of the interviewees.  Figure 5 shows the central role that the National Tumor Bank may 
play in INCA´s scientific research if the efforts towards the development of new 
compounds continue to advance in the institution. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 – The role played by the National Tumor Bank in INCA´s research 
Source: by the authors 
The National Tumor Bank was considered by the research coordination team as 
one of the milestones in the change of direction of the R&D strategies and policies at 
the institute, which is in line with the importance, highlighted in the literature, of 
creating and managing biobanks that support research in life sciences (McQueen et al, 
2010).   It was seen as an innovation, a structuring project for the research field, which 
initiated its automation process with a biobank that relied on an infrastructure for 
micro dissection and arrays of tissues and DNA, up to the point of implementing the 
Banco Nacional de Tumores (SISBNT) – National Tumor Bank System. 
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Thus, there was a clear strategic purpose behind the development and 
implementation of the National Tumor Bank system, which was aligned with the view, 
as far as innovation is concerned, predominant at that time at INCA´s executive level. 
This high level of congruence was a determinant for the project to be supported by the 
institute’s top management, making it a priority at the institution. It is confirmed in 
this research the idea that the commitment of the main stakeholders of the organization 
and a strong organizational leadership are highly necessary to the success of the 
implementation of information systems in healthcare organizations (Cresswell & 
Sheikh, 2013; Gruber, Cummings, LeBlanc, & Smith, 2009). 
Currently, INCA is a landmark institution in Latin America when it comes to 
clinical trials for stages 1, 2 and 3 of oncology therapeutic class. Around 80% of 
INCA´s clinical studies are sponsored by major global pharmaceutical companies, 
which use these clinical studies in multicenter tests of new drugs or for new uses for 
already existing active principles.  The remaining 20% of the studies is requested by 
INCA´s own researchers or by the Rede Nacional de Pesquisa Clínica - National 
Clinical Research Network. 
INCA´s basic research areas involve experiments focused on the identification 
of the genetic base of the disease and on the identification of molecules for the 
treatment of various cancer types. Five years ago, together with the experiments 
performed in physical laboratories, INCA, reflecting the change in the R&D profile 
under development, structured its Bioinformatics and Computational Biology, which 
carry out in silico analyses of the date generated in experiments in Genomics, 
Proteomics, molecular modeling and virtual screening. 
The creation of a translational research laboratory was seen by INCA´s 
managers as an essential step towards the effective integration of basic research where 
Bioinformatics is found - and clinical trials focused on drug projects, contributing to 
reducing the academic characteristic that INCA´s research used to have a short time 
ago.   As a rule, translational research is described in the literature as a link or a linear 
integration process of basic research into clinical trials (Goldblat & Lee, 2010). At 
INCA, as seen in Figure 5, the manager of the translational research laboratory 
manager understands that his projects are going to play an increasingly interactive role. 
In line with this perspective, some projects carried out at INCA stemmed from 
problems observed in clinical practice, giving rise to research questions, whose 
answers made it necessary to resort to basic research in order to develop the 
hypothesis, retesting it in the translational or clinical context. The cells stored at the 
National Tumor Bank lie central in the clinical and retro alignment process, whose 
moving around is managed by the Banco Nacional de Tumores (SISBNT) – National 
Tumor Bank System. 
The Research Center managers understood that INCA was qualifying itself, 
based on the new process and systems of Information and Communication 
Technologies, on the ongoing efforts for the construction of an institutional/legal 
landmark cancer research in order to support the network of Brazilian researchers 
(many of them in the academic community who do not have resources to advance their 
research towards pre-clinical and clinical study stages). Herein, SISBNT plays a 
critical role by providing objective conditions for this research to advance up to the 
point it reaches higher complexity stages that involve a higher need for resources, such 
as stage 1, 2 and 3 pre-clinical and clinical tests. 
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It is possible to see the important role of leaderships at the institute regarding 
the integration of the different areas of the organization, with the support of systems 
that would interconnect, improve and speed up relevant information flows between 
these areas. As a matter of fact, efforts to integrate and bring together the various 
sectors within the organization and its ICTs are usually seen as critical for the 
successful implementation of computational systems in the area of healthcare 
(Cresswell & Sheikh, 2013; Gagnon et al., 2010).  Actually, it seemed that a consensus 
existed between the various actors involved in the process of adoption of the Banco 
Nacional de Tumores (SISBNT) – National Tumor Bank System. 
This consensus related to the need for development and implementation of a 
system that properly supported the joint efforts of cancer care providers and 
researchers.   Thus, the investigated case provides additional empirical support to how 
important it is for users to understand the potential benefits arising from technology 
and the effective commitment to the project (Yarbrough & Smith, 2007; Yusof, 
Stergioulas, & Zugic, 2007). 
The role played by the Information Technology Division (ITD) in the design 
and implementation of SISBNT showed evidence that good practices in information 
management can contribute to the consolidation of the biobank in biopharmaceutical 
organizations, which adopt translational research in the oncology therapeutic class, as 
highlighted by Goebell & Morente (2010). The ability of the ITD team, in particular its 
manager, to discuss with the various stakeholders of the project, to understand their 
expectations and to define an IT solution that respected autonomy needs of the various 
areas - and at the same time, that promoted its integration - was essential for the 
success of the initiative. 
As frequently cited in the literature (Cresswell & Sheikh, 2013; Gagnon et al., 
2010; Yarbrough & Smith, 2007), the good relationship between the areas involved in 
the adoption of the new system was critical for the alignment of roles, responsibilities, 
activities information flows and functionalities inserted into the scope of  the Banco 
Nacional de Tumores (SISBNT) – National Tumor Bank System. As highlighted by 
Yusof et al. (2007), “technological, human and organizational factors are equally 
important  [to the success of IT adoption in healthcare organizations], as well as the 
alignment between them”. 
At the end of data collection, it was noticed that although the connection 
between the different research areas of the Research Center was still fragmented, the 
basic research areas, both in physical laboratories and in Computational Biology, 
already performed experiments proposed by translational research and they were 
assessed in clinical trials. Data from SISBNT were already used in basic bench 
research, in some translational research laboratory projects and in clinical trials. 
In part, due to the fact that the in silico research still did not focus on the 
national drug program, the experiments in Bioinformatics had not accessed the data 
from SISBNT until the end of 2013, although this area had declared its intention to do 
so shortly.  Among the initiatives that contributed for this to happen were the increase 
in the number of stored samples at SISBNT and the emergence of powerful tools of 
genetic sequencing and High Performance Computing, acquired in October 2001 and 
June 2012. 
It is worthy of mentioning, however, that as Bioinformatics and translational 
research, and the National Tumor Bank itself, had been recently created in the 
institution - the adoption of techniques or data mining tools highlighted in the 
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literature - with a focus on the recognition of standards, structures and rules (Krysiak-
Baltyn et al, 2014), was not evident at INCA by the time this study was conducted. 
 
5. CONCLUSIONS 
 
In response to the previously defined research question, the analysis of INCA´s 
Banco Nacional de Tumores (SISBNT) – National Tumor Bank System illustrates how 
a biobank with the support of modern information and communication technologies 
can contribute to the improvement of scientific research in oncology therapeutic class. 
The benefits of such an innovation are immediately reflected in the improvement of 
the access to useful knowledge and in the increase of operational efficiency in R&D 
management. Other benefits are reflected as an increased focus on patients’ 
expectations and their satisfaction, as well as on improvements in transference and 
dissemination of knowledge. 
It is clear in the analysis of the evidence that the implementation of such an 
initiative demanded, before anything else, that the involved managers clearly 
understand the process of use of this information and the meaning of the initiative for 
the repositioning of INCA as an oncology innovation center. It was also confirmed that 
SISBNT represented an important innovation in the institute´s IT area, which meant a 
paradigm shift at INCA´s Research Center. Such an innovation contributed to, 
according to the interviewees´ own answers, positioning INCA as the only Brazilian 
organization that boasts technical conditions to perform all the stages of research 
focused on the development of new drugs in oncology therapeutic class.  It was also 
clear that the Banco Nacional de Tumores (SISBNT) – National Tumor Bank System - 
is regarded by researchers as a critical tool, not only due to the relevance that the data 
contains, but also due to the fact it was developed in compliance with good practices 
from Information Science. This fact keeps the organization from resorting to database 
and technological platforms, which are unsuitable to the objectives of knowledge 
management, and to the integration of the technological co-development process, as 
these practices seem to be commonplace in R&D areas, which do not boast a suitable 
IT support. 
The explanatory nature of this research imposes some limitations to the scope 
of the aforementioned conclusions. First, there is no intention to exhaust the discussion 
about the contributions to a biobank in cancer technological innovation, in particular 
regarding the organizational mechanisms and processes, which are necessary to its 
development and management.  In addition, as one of the authors of this research is the 
person in charge of the implementation of SISBNT, the subjectivity in the treatment of 
the answers given cannot be ruled out. At last, the context of this research, INCA, a 
public organization associated with the Health Ministry of Brazil, imposes restrictions 
on the generalization of results for other private companies and for other countries. 
Despite the aforementioned limitations, this research contributed to theory and 
practice as it highlights the importance of bringing together of IT and R&D in cancer 
research, as seen in the case of INCA´s Banco Nacional de Tumores (SISBNT) – 
National Tumor Bank System.  From this finding, a question for further research is 
raised: what organizational mechanisms and processes can contribute to a better 
integration of IT into basic, translational and clinical research? Lastly, it is understood 
that R&D and IT managers of Brazilian biopharmaceutical companies can use the case 
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herein described in order to learn important lessons that aim to improve their 
innovation efforts.  
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